Precision Analgesia for Cardiac Surgery

Sponsor
Kathirvel Subramaniam (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05612399
Collaborator
(none)
400
1
20
20

Study Details

Study Description

Brief Summary

The proposed research is an important extension of an ongoing perioperative personalized analgesia and intravenous opioid pharmacogenetic research. This research focuses on two of the most commonly used oral opioid analgesics, oxycodone, and methadone in elderly adults undergoing cardiac surgery.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Cardiac surgery patients often experience significant acute postoperative pain, and untreated or undertreated pain has consequences. Each year, 900,000 painful cardiac surgeries occur in the US alone. Pain associated with cardiac surgery results from surgical incision, sternal retraction, internal mammary artery harvesting, saphenous vein removal, placement of mediastinal and chest drains, sternal wires, and release of pro-inflammatory mediators after tissue injury. One study reported that 49%, 62%, and 78% of patients reported severe pain at rest, movement, and coughing, respectively after coronary artery bypass surgery (CABG). Another study showed that 61.4% of patients undergoing cardiac surgery reported moderate to severe pain. Inadequate pain treatment is common in cardiac surgery due to health care providers' fears of causing cardiorespiratory compromise. Poor pain control can trigger sympathoadrenal responses leading to cardiac arrhythmias and myocardial ischemia, restrict mobility to cause venous thrombosis, impair clearance of secretions leading to pulmonary complications such as atelectasis and pneumonia, decrease patient satisfaction and predispose to the development of chronic, persistent surgical pain (CPSP).

    Improving clinical practice by shifting paradigms: Our research is transformative and will evolve current reactive clinical practice towards proactive precision methods based on genetic risks for surgical pain and ORADE in elderly vulnerable population. This is the first effort to move in the direction of personalizing perioperative opioid use with precise dosing to improve safety and efficacy in cardiac surgery. Preoperative genotyping-based clinical decisions are expected to support clinical implementation in real-world settings. Importantly, investigators will be able to reach beyond the current best-in-class outcomes with precision multi-dose methadone analgesia based on proactive genetic risk identification to maximize safety and efficacy of opioids in all cardiac surgical patients and positively impact socio-economic outcomes in the future. By addressing these critical barriers, this research will help physicians identify patients at risk and improve the safety and efficacy of opioids and surgical pain management while preventing OD, misuse, overdose, and deaths.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    400 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Precision Perioperative Methadone Use in Adult Cardiac Surgical Patients to Reduce Opioid Use Adverse Effects While Improving Analgesia and Outcomes
    Anticipated Study Start Date :
    Apr 1, 2023
    Anticipated Primary Completion Date :
    Dec 1, 2024
    Anticipated Study Completion Date :
    Dec 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. Determine Genetic Factors - Opioid Related Adverse Events (RD) [Immediately post-surgery during hospital stay]

      Respiratory depression will be measured with binary yes/no responses obtained either via self-report from the patient or reported by the clinical care staff.

    2. Determine Genetic Factors - Opioid Related Adverse Events (PONV) [Immediately post-surgery during hospital stay]

      Post-operative nausea and vomiting will be measured with binary yes/no responses obtained either via self-report from the patient or reported by the clinical care staff.

    3. Determine Genetic Factors - Opioid Related Adverse Events (Excessive Sedation) [Immediately post-surgery during hospital stay]

      Excessive sedation will be measured with binary yes/no responses obtained either via self-report from the patient or reported by the clinical care staff.

    4. Determine Genetic Factors - Uncontrolled severe pain [Immediately post-surgery during hospital stay]

      We postulate that specific CYP2B6, ABCB1, OPRM1, FAAH, and ORM1 genetic variants identify patients at risk for poor pain relief and ORADE with methadone in the immediate post-surgical period. Pain will be measured by the Numerical Rating Scale (NRS) in which 0 = no pain at all and 10 = worst pain imaginable. This will be self-reported responses by the patient.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    60 Years to 110 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Elderly cardiac surgical patients over 60 years of age
    Exclusion Criteria:
    • Methadone allergy

    • Morbid obesity (BMI >40kg/cm2)

    • Severe sleep apnea

    • Severe pulmonary disease requiring oxygen therapy

    • Preoperative mechanical circulatory support

    • Emergency surgery

    • Liver disease (liver enzymes more than two times normal)

    • End-stage renal disease requiring dialysis

    • Serum creatinine more than 2.0mg

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 UPMC Presbyterian Hospital Pittsburgh Pennsylvania United States 15213

    Sponsors and Collaborators

    • Kathirvel Subramaniam

    Investigators

    • Principal Investigator: Kathirvel Subramaniam, MD, MPH, University of Pittsburgh
    • Study Director: Amy Monroe, MPH, MBA, University of Pittsburgh

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Kathirvel Subramaniam, Associate Professor, University of Pittsburgh
    ClinicalTrials.gov Identifier:
    NCT05612399
    Other Study ID Numbers:
    • STUDY22060101
    First Posted:
    Nov 10, 2022
    Last Update Posted:
    Jan 10, 2023
    Last Verified:
    Jan 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 10, 2023